FDA Completeness Assessment Correspondence

The FDA has made available Completeness Assessment Correspondence, authored by the Center for Drug Evaluation and Research (CDER). While no documents are directly viewable or downloadable within the provided summary, a link to the attachment metadata suggests these are official communications regarding the completeness of regulatory submissions.

This notice is primarily informational for drug manufacturers and pharmaceutical companies. Compliance officers should note that this correspondence may relate to specific drug applications and could require internal review or action depending on the content of the actual documents, which are accessible via the provided download link. No immediate compliance actions are mandated by this notice itself, but it signals ongoing communication between the FDA and applicants.